Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,466 Mln
Revenue (TTM)
$6 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.2
Industry P/E
--
EV/EBITDA
-6.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.9
Face value
--
Shares outstanding
126,998,000
CFO
$-811.94 Mln
EBITDA
$-781.36 Mln
Net Profit
$-756.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
| -40.8 | 8.8 | -34.5 | 62.8 | 18.4 | -13.1 | -9.2 |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
| 784.0 | -62.2 | -39.4 | -43.5 | 15.2 | 78.9 | -29.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mesoblast - ADR
|
11.7 | 1,465.6 | 5.7 | -103.4 | -906.0 | -22 | -- | 3.2 |
| 2.5 | 3.3 | 0.6 | -8.0 | -1,245.8 | -178.5 | -- | 0.0 | |
| 0.3 | 4.2 | 7.5 | -9.0 | -144,731.8 | -0.3 | -- | 0.7 | |
| 0.6 | 200.2 | 0.0 | -2.4 | -- | 299.5 | -- | 0.0 | |
| 7.8 | 202.1 | 43.0 | -75.0 | -167.4 | -40.8 | -- | 1.3 | |
| 2.3 | 16.4 | 2.7 | -8.2 | -275.0 | -2480.5 | -- | 7.9 | |
| 1.6 | 158.9 | 41.6 | -202.0 | -370.3 | -136.3 | -- | 1.5 | |
| 0.5 | 16.5 | 0.0 | 2,778.9 | -268,238.4 | 33.7 | 4.6 | 1.0 | |
| 197.9 | 12,103.8 | 16,084.1 | 1,196.9 | 10.9 | 17.5 | 10.6 | 1.8 | |
| 1.1 | 3.8 | 0.0 | -3.3 | -- | -109.8 | -- | 1.1 |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal... lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Address: 55 Collins Street, Melbourne, VIC, Australia, 3000 Read more
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Headquarters
Melbourne, VIC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mesoblast Limited - ADR stood at $ 723 Mln as on 31-Dec-24
The share price of Mesoblast Limited - ADR is $11.72 (NASDAQ) as of 16-May-2025 16:00 EDT. Mesoblast Limited - ADR has given a return of 18.41% in the last 3 years.
Mesoblast Limited - ADR has a market capitalisation of $ 1,466 Mln as on 15-May-2025. As per Value Research classification, it is a company.
The P/B ratio of Mesoblast Limited - ADR is 3.18 times as on 15-May-2025, a 18% discount to its peers’ median range of 3.87 times.
Since, TTM earnings of Mesoblast Limited - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mesoblast Limited - ADR and enter the required number of quantities and click on buy to purchase the shares of Mesoblast Limited - ADR.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Address: 55 Collins Street, Melbourne, VIC, Australia, 3000
The CEO & director of Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons). is Mesoblast Limited - ADR, and CFO & Sr. VP is Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons).
There is no promoter pledging in Mesoblast Limited - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
20
|
|
|
16
|
|
|
2
|
|
|
2
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
1,210
|
| Mesoblast Limited - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-21.95
|
|
Operating margin(%)
|
-906.03
|
|
Net Margin(%)
|
-1822.77
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mesoblast Limited - ADR was $0 Mln.
$-0.23
(
